XML 23 R12.htm IDEA: XBRL DOCUMENT v3.20.2
Stock-Based Compensation
 9 Months Ended
Oct. 31, 2020
Share-based Payment Arrangement [Abstract]  
Stock-Based Compensation Stock-Based Compensation
The compensation costs that have been charged against income were as follows (in thousands):

13-Weeks Ended39-Weeks Ended
October 31,
2020		November 2,
2019		October 31,
2020		November 2,
2019
Stock-based compensation expense by type:
Stock options
$— $— $90 $92 
Restricted stock units968 859 2,615 1,576 
Employee stock purchases
23 22 93 73 
Director deferred compensation23 24 71 70 
  Total stock-based compensation expense1,014 905 2,869 1,811 
Income tax benefit recognized244 295 672 428 
  Stock-based compensation expense, net of income tax$770 $610 $2,197 $1,383 

Expense for restricted stock units is shown net of forfeitures of approximately $2,300 and $36,000 for the 13-weeks ended October 31, 2020 and November 2, 2019, respectively. Expense for restricted stock units is shown net of forfeitures of $0.9 million and $1.8 million for the 39-weeks ended October 31, 2020 and November 2, 2019, respectively.
We have granted the following equity awards:

13-Weeks Ended39-Weeks Ended
October 31,
2020		November 2,
2019		October 31,
2020		November 2,
2019
Stock options
— — 27,000 16,798 
Restricted stock unit awards
— 6,934 337,749 229,528 
Performance-based restricted stock unit awards
— — — 34,300 
Deferred stock units
597 1,023 3,860 3,338 
At October 31, 2020, the total compensation costs not yet recognized related to unvested restricted stock unit awards was $5.3 million and the weighted-average period over which such awards are expected to be recognized is 2.5 years. There were no unrecognized compensation costs related to unvested stock options at October 31, 2020.

During the 13-weeks ended October 31, 2020 and November 2, 2019, no stock options were granted. The weighted-average grant date fair value of stock options granted during the 39-weeks ended October 31, 2020 and November 2, 2019 was $3.33 and $5.46 per share, respectively.
Under the 2012 Non-Employee Director Equity Plan (2012 Plan), no shares of our common stock were awarded during the 13-weeks ended October 31, 2020 or November 2, 2019. No shares of our common stock were awarded during the 39-weeks ended October 31, 2020 as part of the annual equity award to directors. A total of 13,858 shares of our common stock were awarded during the 39-weeks ended November 2, 2019, as part of the annual equity award to directors.
The number of shares purchased, the average price per share and the weighted-average grant date fair value of shares purchased through our employee stock purchase plan were as follows:
13-Weeks Ended39-Weeks Ended
October 31,
2020		November 2,
2019		October 31,
2020		November 2,
2019
Shares purchased4,605 5,652 33,506 21,205 
Average price per share$17.66 $15.73 $10.21 $13.99 
Weighted-average fair value at grant date$4.99 $4.16 $3.71 $3.96